Drug intelligence / Profile preview

Dengusiil

Development stage: Phase 1
Lead developer: Serum Institute of India
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**Dengusiil** is an investigational, live-attenuated tetravalent dengue vaccine developed by Serum Institute of India for prevention of dengue fever. The vaccine contains live attenuated dengue virus components representing dengue virus serotypes 1, 2, 3, and 4, with each serotype included to induce broad neutralizing immune responses against all four dengue serotypes. It has been evaluated as a single subcutaneous dose in healthy adults and subsequently entered a seamless Phase 1/2 study in Indian adults and children aged over 2 years.

Other names: Dengue tetravalent vaccine live attenuated

Beyond the preview

Go deeper on Dengusiil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dengusiil.

Explore the full profile